All In Biotech

Drug Trial Radar · NCT07038551

Prophylactic Use of Naldemedine on Opioid-induced Nausea and Vomiting in Patients With Cancer: POSEIDON Study

Prophylactic Use of Naldemedine on Opioid-Induced Nausea and Vomiting in Patients With Cancer: A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study

Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Jun 20, 2025

Primary completion

Feb 13, 2026

Study completion Feb 13, 2026

Sponsor

Lead sponsor
International University of Health and WelfareAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shionogi
First posted
Jun 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Opioid analgesics can cause side effects such as constipation, nausea, and vomiting by acting on opioid receptors widely distributed in the peripheral nervous system. This can sometimes make it difficult to achieve and maintain pain relief and continue pain treatment. Among these side effects, nausea and vomiting are specifically referred to as opioid-induced nausea and vomiting (OINV). OINV is known to occur during the initial administration or dose escalation of opioid analgesics, and it not only decreases the quality of life for patients but also reduces adherence to opioid analgesics, which can have a negative impact on pain management. Therefore, appropriate management is crucial. While the administration of conventional antiemetic drugs is recommended for the treatment of OINV, there is a lack of high-quality studies evaluating their effectiveness, and studies comparing treatment effects with a placebo have not been reported. The objective is to verify the effectiveness of naldemedine in preventing OINV in patients starting opioid analgesics for cancer

Conditions

  • Opioid-Induced Nausea and Vomitting(OINV)

Interventions

  • NaldemedineDrug

    over-encapsulated capsule of either 0.2 mg of naldemedine

  • PlaceboDrug

    over-encapsulated capsule of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients who achieved a Complete Response on Day 5 (CR5), defined as no vomiting up to 120 hours after starting opioid analgesic and no use of rescue antiemetic medications.Time frame: 120 hours

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Toyohashi municipal hospital

    Toyohashi, Aichi-ken, Japan

  • IUHW Narita Hospital

    Narita, Chiba, Japan

  • Iizuka Hospital

    Iizuka, Fukuoka, Japan

  • Hiroshima Prefectural Hospital

    Hiroshima, Hiroshima, Japan

  • Kansai Rosai Hospital

    Amagasaki, Hyōgo, Japan

  • National Hospital Organization HIMEJI M edical Center

    Himeji, Hyōgo, Japan

  • Hyogo Prefectural Nishinomiya Hospital

    Nishinomiya, Hyōgo, Japan

  • University of Tsukuba Hospital

    Tsukuba, Ibaragi, Japan

  • St. Marianna University School of Medicine

    Kawasaki, Kanagawa, Japan

  • Kanagawa Dental University Yokohama Clinic

    Yokohama, Kanagawa, Japan

  • Kyoto University Hospital

    Kyoto, Kyoto, Japan

  • Osaki Citizen Hospital

    Ōsaki, Miyagi, Japan

  • Kindai University Nara Hospital

    Ikoma, Nara, Japan

  • Niigata Cancer Center Hospital

    Niigata, Niigata, Japan

  • Beppu Medical Center

    Beppu, Oita Prefecture, Japan

  • Osaka Red Cross Hospital

    Osaka, Osaka, Japan

  • National Cancer Center Hospital

    Chuo Ku, Tokyo, Japan

  • Cancer Institute Hospital of Japanese Fo undation for Cancer Research

    Tokyo, Tokyo, Japan

  • Showa University Koto Toyosu Hospital

    Tokyo, Tokyo, Japan

  • Toyama University Hospital

    Toyama, Toyama, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.